⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15903657 | 1.00 | — | — | |
| SCHEMBL1438741 | 1.00 | — | — | |
| SCHEMBL7020133 | 0.74 | — | — | |
| SCHEMBL6622723 | 0.74 | — | — | |
| SCHEMBL5025918 | 0.74 | — | — | |
| SCHEMBL15692366 | 0.74 | — | — | |
| SCHEMBL14092974 | 0.74 | TSHR (0.32) | — | |
| SCHEMBL14738101 | 0.72 | — | — | |
| SCHEMBL16284653 | 0.72 | — | — | |
| SCHEMBL27414006 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112424188-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| WO-2014141104-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20120108564-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120108564-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |